Reviewing IceCure Medical (NASDAQ:ICCM) and Pediatrix Medical Group (NYSE:MD)

Pediatrix Medical Group (NYSE:MD) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Risk and Volatility

Pediatrix Medical Group has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500.

Valuation & Earnings

This table compares Pediatrix Medical Group and IceCure Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pediatrix Medical Group	$1.91 billion	0.89	$165.39 million	$1.94	10.57
IceCure Medical	$3.38 million	8.11	-$15.06 million	($0.24)	-1.56

Pediatrix Medical Group has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Pediatrix Medical Group, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

97.7% of Pediatrix Medical Group shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 0.9% of Pediatrix Medical Group shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Pediatrix Medical Group and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pediatrix Medical Group	8.64%	19.59%	7.75%
IceCure Medical	-445.61%	-221.04%	-118.89%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Pediatrix Medical Group and IceCure Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pediatrix Medical Group	0	5	1	1	2.43
IceCure Medical	1	1	1	0	2.00

Pediatrix Medical Group currently has a consensus price target of $19.80, suggesting a potential downside of 3.40%. IceCure Medical has a consensus price target of $2.64, suggesting a potential upside of 603.04%. Given IceCure Medical’s higher probable upside, analysts clearly believe IceCure Medical is more favorable than Pediatrix Medical Group.

Summary

Pediatrix Medical Group beats IceCure Medical on 11 of the 14 factors compared between the two stocks.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals, including pediatric nurse practitioners, echocardiographers, other diagnostic technicians, and exercise physiologists; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians, pediatric gastroenterologists; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.